{"title":"符合移植条件的R/R DLBCL患者使用格列菲坦单抗加化疗可获益","authors":"Diana Romero","doi":"10.1038/s41571-024-00975-y","DOIUrl":null,"url":null,"abstract":"<p>Chimeric antigen receptor (CAR) T cells have emerged as an effective treatment option for patients with relapsed and/or refractory (R/R) diffuse large B cell lymphoma (DLBCL) who are ineligible for autologous stem-cell transplantation (ASCT), although owing to manufacturing and access-related limitations many patients receive rituximab plus gemcitabine–oxaliplatin. Now, data from the phase III STARGLO trial show that addition of the CD20 × CD3 bispecific T cell engager glofitamab to chemotherapy provides an overall survival (OS) benefit over the rituximab regimen in this setting.</p><p>Patients were randomly allocated to receive gemcitabine–oxaliplatin plus either glofitamab (<i>n</i> = 183) or rituximab (<i>n</i> = 91). Most patients (63%) had received only one prior line of therapy. OS was the primary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"8 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCL\",\"authors\":\"Diana Romero\",\"doi\":\"10.1038/s41571-024-00975-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Chimeric antigen receptor (CAR) T cells have emerged as an effective treatment option for patients with relapsed and/or refractory (R/R) diffuse large B cell lymphoma (DLBCL) who are ineligible for autologous stem-cell transplantation (ASCT), although owing to manufacturing and access-related limitations many patients receive rituximab plus gemcitabine–oxaliplatin. Now, data from the phase III STARGLO trial show that addition of the CD20 × CD3 bispecific T cell engager glofitamab to chemotherapy provides an overall survival (OS) benefit over the rituximab regimen in this setting.</p><p>Patients were randomly allocated to receive gemcitabine–oxaliplatin plus either glofitamab (<i>n</i> = 183) or rituximab (<i>n</i> = 91). Most patients (63%) had received only one prior line of therapy. OS was the primary end point.</p>\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2024-11-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-024-00975-y\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-024-00975-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCL
Chimeric antigen receptor (CAR) T cells have emerged as an effective treatment option for patients with relapsed and/or refractory (R/R) diffuse large B cell lymphoma (DLBCL) who are ineligible for autologous stem-cell transplantation (ASCT), although owing to manufacturing and access-related limitations many patients receive rituximab plus gemcitabine–oxaliplatin. Now, data from the phase III STARGLO trial show that addition of the CD20 × CD3 bispecific T cell engager glofitamab to chemotherapy provides an overall survival (OS) benefit over the rituximab regimen in this setting.
Patients were randomly allocated to receive gemcitabine–oxaliplatin plus either glofitamab (n = 183) or rituximab (n = 91). Most patients (63%) had received only one prior line of therapy. OS was the primary end point.
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
